Skip to main content
. 2017 Apr 5;7:45703. doi: 10.1038/srep45703

Figure 6.

Figure 6

Median PFS stratified on the basis of having 0 (Inline graphic), 1 (Inline graphic), 2 (Inline graphic) or 3 (Inline graphic) side-effects related to Regorafenib treatment. Median PFS were respectively 2.25 vs 3.60 vs 5.63 vs 4.32 months, p of the whole group <0.0001).